Headquartered in Burlingame, CA Fiscal year ends December NASDAQ: INVA inva.com
Innoviva is a diversified biopharmaceutical company operating three core business lines: a royalties portfolio from respiratory assets partnered with GSK (including RELVAR/BREO ELLIPTA and ANORO ELLIPTA), a critical care and infectious disease commercial platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets. IST's marketed products include GIAPREZA for septic or distributive shock, XACDURO for hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii, XERAVA for complicated intra-abdominal infections, ZEVTERA (an advanced-generation cephalosporin antibiotic), and NUZOLVENCE for uncomplicated urogenital gonorrhea. The company also recently launched Nortiva Bio, a wholly-owned subsidiary developing the LYNX long-acting oral drug delivery platform designed to convert daily oral medications into less frequent dosing regimens. Innoviva's strategic healthcare investment portfolio includes significant positions in Armata Pharmaceuticals and other healthcare companies, with a total portfolio value of approximately $669.5 million. Updated
If you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t ring a bell. Denner is the CEO and CIO of Sarissa Capital…
Innoviva is a diversified biopharmaceutical company operating three core business lines: a royalties portfolio from respiratory assets partnered with GSK (including RELVAR/BREO ELLIPTA and ANORO ELLIPTA), a critical care and infectious disease commercial platform known as Innoviva Specialty Therapeutics (IST), and a…
The Wall Street consensus 12-month price target for INVA is $35.00.
